Answers are grounded in this paper and cite their sources.
Secondly, expenditure on drugs for the elderly is proportionately greater. Figures from the Association of the British Pharmaceutical Industry for 1984 showed that of 315 million prescriptions, 77*6% were for people exempt from prescription charges, of whom about half were elderly. Thus 35-40% of drug expenditure is on the elderly (these figures relate to those of pensionable age), who constitute 15 16% of the total population. Thirdly, there is a disturbing apparent increase with age in susceptibility to adverse drug reactions. This has been more difficult to show historically but is an undoubted fact of life, particularly with certain drug groups such as several acting on the central nervous system, those with autonomie effects, and a variety of cardiovascular compounds. Information has been derived from anecdotal reports, expensive drug surveillance programmes in hospitals, detection systems for adverse drug reactions (such as the yellow card system of the Committee on Safety of Medicines), and reports on samples of selected patients, such as those being admitted to psychiatric units or departments of geriatric medicine. Underreporting and exploitation The extent to which age is perceived as conferring increased vulnerability may be positively weighted by the greater extent of prescribing but negatively weighted by a widespread failure to detect and diagnose iatrogenic disease in the elderly and by the underreporting of adverse reactions to regulatory bodies. Such underreporting is particularly likely where the adverse effect can be readily explained as an exaggeration of the drug's main action or one of its known side effects?that is, a type A or dose related effect. Many older people, particularly those who are disabled, tend to become reconciled to less than optimal health; hence neither they nor their carers complain readily, and the more subtle, if debilitat? ing, consequences of iatrogenic disorder are readily overlooked unless prescribers remain alert. The rapid growth in the numbers of new drugs means that special steps must be taken to protect the interests of this vulnerable and potentially exploitable section of the population, particularly as much pharmaceutical innovation is directly aimed at the relief of longstanding disorders prevalent within the age group rather than at radical short term cure. This paper will first, for completeness, outline the main areas of importance that have emerged from research into drugs in the elderly, though there are numerous recent reviews of the topic.17 Secondly, the possible implications for future prescribing, drug research, and drug development will be discussed.
No takes yet. Share an insight, caveat, or question.
C. G. Swift (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: